Full Access To HCV Drugs Would Save Money Long-Term, Study Finds
This article was originally published in The Pink Sheet Daily
Restricting coverage to the sickest HCV patients saves individual Medicaid programs money in the short-term, a study by ISPOR finds, but increases costs for Medicare in the longer-term.
You may also be interested in...
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.